effect of extended-release niacin/laropiprant combination on plasma adiponectin and insulin resistance in chinese patients with dyslipidaemia
Clicks: 180
ID: 221644
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
180 views
35 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #84 of 193 articles by views in international journal of psychology : journal international de psychologie
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 193 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Objectives. This study examined whether the increase of adiponectin associated with extended-release (ER) niacin/laropiprant combination attenuates the adverse effect of niacin on glucose and insulin resistance in Hong Kong Chinese patients with dyslipidaemia. Methods. Patients (N=121) were treated with ER niacin/laropiprant 1 g/20 mg for 4 weeks and then the dose was doubled for an additional 8 weeks. Measurements of fasting lipids, glucose, insulin, and adiponectin were performed at baseline and during the study. Results. There were significant (P<0.001) increases in glucose (9.4 ± 13.1%), insulin (70.2 ± 91.0%), HOMA-IR (87.8 ± 103.9%), and adiponectin (169.3 ± 111.6%). The increase in adiponectin was significantly associated with increase in glucose (r=0.221, P<0.05), insulin (r=0.184, P<0.05), and HOMA-IR (r=0.237, P<0.01) and the association remained significant after adjustment for changes in body weight or body fat mass. Conclusion. Treatment with ER niacin/laropiprant led to a significant increase in adiponectin levels but worsening of glucose levels and insulin resistance, and the increase in adiponectin and insulin resistance were correlated suggesting the increase in adiponectin did not ameliorate the deterioration in insulin resistance. Clinical trial is registered with number on WHO-ICTRP: ChiCTR-ONC-10001038.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (78 words).
Try re-searching for a better abstract.
| Reference Key |
hu2015diseaseeffect
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Miao Hu;Ya-Ling Yang;Daisaku Masuda;Shizuya Yamashita;Brian Tomlinson |
| Journal | international journal of psychology : journal international de psychologie |
| Year | 2015 |
| DOI |
10.1155/2015/154014
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.